Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Huperzine A wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
4 of 5 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
4 of 4 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Huperzine A and Oxiracetam have evidence — compare verdict strength side-by-side.
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
800-2400mg daily in divided doses
Morning and early afternoon, Divided into 2-3 doses, With choline source
Oxiracetam powder or capsules
2-4 weeks
30-60 minutes
2-4 weeks
During use
1-2 weeks
1-2 weeks
1-2 weeks
If choline-deficient
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=289
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
Clinical efficacy and safety of nicergoline combined with oxiracetam in the treatment of vascular cognitive impairment
Pakistan journal of pharmaceutical sciences (2020) · Rct · n=120
The combined group had the highest effective rate and the total effective rate was 93.3%.
A Meta-Analysis of Au/Polypropionic Acid Nanoparticles Loaded with Olacetam for the Treatment of Vascular Cognitive Impairment
Journal of nanoscience and nanotechnology (2020) · Meta analysis
The results of the meta-analysis showed that compared with placebo and other medications, oxiracetam significantly improved the mental status of patients, Concise Mental State Checklist score [mean difference (MD)= 5.29, P < 0.01] and Montreal Cognitive Assessment score (MD = 4.32, P < 0.01).
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Based on meta-analysis showing MMSE improvement (WMD: 2.27) in dementia populations. Evidence primarily from dementia patients, limited data in healthy individuals. Quality concerns noted in systematic reviews regarding study methodology.
Based on multiple meta-analyses showing cognitive improvements in vascular dementia and stroke populations. One major RCT (n=500) showed no benefit for post-stroke cognitive impairment, limiting confidence. Effects may be population-specific and less pronounced in healthy individuals.
AI-estimated from published studies. Interpret as directional guidance.
Huperzine A has a higher evidence score (6/10 vs 5/10) and wins in 2 of 3 categories.
For sharpen focus, Huperzine A has a higher relevance score (80 vs 75).
No known interactions between Huperzine A and Oxiracetam have been documented in our database. However, always consult a healthcare provider before combining supplements.